Insulin Sensitivity during Combined Androgen Blockade for Prostate Cancer
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
CONTEXT: GnRH agonists markedly increase fat mass in men with prostate cancer, but little is known about the effects of treatment on insulin sensitivity. OBJECTIVE: The objective of the study was to assess the effects of short-term GnRH agonist treatment on insulin sensitivity. DESIGN: This was a prospective 12-wk study. SETTING: The study was conducted at a general clinical research center. PATIENTS OR OTHER PARTICIPANTS: We studied 25 men with locally advanced or recurrent prostate cancer, no radiographic evidence of metastases, no history of diabetes mellitus, and no evidence of diabetes mellitus at baseline visit. INTERVENTION: Leuprolide depot and bicalutamide were used in the study. MAIN OUTCOME MEASURES: Oral glucose tolerance tests and body composition assessment by dual-energy x-ray absorptiometry were performed at baseline and wk 12. The primary study outcome was change in insulin sensitivity index. RESULTS: Mean (+/- se) percentage fat body mass increased by 4.3 +/- 1.3% from baseline to wk 12 (P = 0.002). Insulin sensitivity index decreased by 12.9 +/- 7.6% (P = 0.02). Insulin sensitivity by homeostatic model assessment decreased by 12.8 +/- 5.9% (P = 0.02). Fasting plasma insulin levels increased by 25.9 +/- 9.3% (P = 0.04). Mean glycosylated hemoglobin also increased significantly (P < 0.001). CONCLUSIONS: Short-term treatment with leuprolide and bicalutamide significantly increased fat mass and decreased insulin sensitivity in men with prostate cancer. These observations suggest that GnRH agonists may increase the risk of diabetes mellitus and cardiovascular disease in older men.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Role of Insulin Resistance in Human Disease
Reaven, G. M. (1988) · Diabetes · doi:10.2337/diab.37.12.1595 · Cited by 12,154
Matsuda, M., & DeFronzo, R. A. (1999) · Diabetes Care · doi:10.2337/diacare.22.9.1462 · Cited by 5,621 · cited 4×
“The whole-body ISI was calculated from fasting plasma insulinandglucoseconcentrationsandmeanplasmainsulinandglucose concentrations during the OGTT, with ISI 10,000/square root of (fasting plasma glucose fasting plasma insulin) (mean OGTT glucose mean OGTT insulin) ( 18 ).”
BackgroundMethodResultInfluentialDeFronzo, R. A., & Ferrannini, E. (1991) · Diabetes Care · doi:10.2337/diacare.14.3.173 · Cited by 4,535 · cited 1×
“The observed increase in HDL cholesterol levels contrasts to the low levels of HDL cholesterol associated with the classic metabolic syndrome (14, 15 ).”
BackgroundPrevalence of Overweight and Obesity Among US Children, Adolescents, and Adults, 1999-2002
Hedley, A. A. (2004) · JAMA · doi:10.1001/jama.291.23.2847 · Cited by 4,460
Yudkin, J. S., Stehouwer, C. D. A., Emeis, J. J., & Coppack, S. W. (1999) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.19.4.972 · Cited by 2,465
Hyperinsulinemia as an independent risk factor for ischemic heart disease
Després, J.-P., Lamarche, B., Mauriège, P., Cantin, B., Dagenais, G. R., Moorjani, S., & Lupien, P.-J. (1996) · New England Journal of Medicine · doi:10.1056/nejm199604113341504 · Cited by 1,699 · cited 1×
“Insulin resistance is a common metabolic abnormality that underlies type 2 diabetes mellitus (11) and is an independentriskfactorforcardiovasculardisease( 12 ,13).Insulin resistance is also linked to a variety of abnormalities associated with cardiovascular disease risk including obesity, hypertension, elevated trigly…”
BackgroundAndrogen Deprivation Therapy for Prostate Cancer
Sharifi, N. (2005) · JAMA · doi:10.1001/jama.294.2.238 · Cited by 1,083 · cited 1×
“nRH AGONISTS ARE the cornerstone of treatment for metastatic prostate cancer and a routine part of management for many men with local and local-regional disease ( 1 ).”
BackgroundFerrannini, E., Natali, A., Bell, P., Cavallo-Perin, P., Lalic, N., & Mingrone, G. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119628 · Cited by 898
Role of Insulin Resistance in Human Disease
Reaven, G. M. (1992) · Medical Science Symposia Series · doi:10.1007/978-94-011-2700-4_10 · Cited by 865
Changes in body composition during androgen deprivation therapy for prostate cancer
Smith, M. R., Finkelstein, J. S., McGovern, F. J., Zietman, A. L., Fallon, M. A., Schoenfeld, D. A., & Kantoff, P. W. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.2.8299 · Cited by 697 · cited 3×
“Consistent with earlier reports ( 5 , 8, 22), we observed that”
BackgroundMethodResultSelf-citationA Prospective Analysis of the HOMA Model: The Mexico City Diabetes Study
Haffner, S. M., Gonzalez, C., Miettinen, H., Kennedy, E., & Stern, M. P. (1996) · Diabetes Care · doi:10.2337/diacare.19.10.1138 · Cited by 553
THE INSULIN RESISTANCE SYNDROME: Definition and Dietary Approaches to Treatment
Reaven, G. M. (2005) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.24.012003.132155 · Cited by 516 · cited 1×
“Obesity is a major correlate of insulin resistance in adults (9, 10 ).”
BackgroundMeigs, J. B., Wilson, P. W. F., Nathan, D. M., D’Agostino, R. B., Williams, K., & Haffner, S. M. (2003) · Diabetes · doi:10.2337/diabetes.52.8.2160 · Cited by 464
Self-citationSmith, J. C., Bennett, S., Evans, L. M., Kynaston, H. G., Parmar, M., Mason, M. D., Cockcroft, J. R., Scanlon, M. F., & Davies, J. S. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.9.7851 · Cited by 458 · cited 2×
“GnRH agonists increase fasting plasma insulin levels in men with prostate cancer ( 7 , 8). In contrast to the other reports, however, our study excluded subjects with prevalent diabetes and evaluated whole-body insulin sensitivity index after a glucose load, a more reliable method for assessment of insulin sensitivity…”
BackgroundResultInfluentialPyörälä, M., Miettinen, H., Laakso, M., & Pyörälä, K. (1998) · Circulation · doi:10.1161/01.cir.98.5.398 · Cited by 349
BERRUTI, A., DOGLIOTTI, L., TERRONE, C., CERUTTI, S., ISAIA, G., TARABUZZI, R., REIMONDO, G., MARI, M., ARDISSONE, P., DE LUCA, S., et al. (2002) · Journal of Urology · doi:10.1016/s0022-5347(05)64985-3 · Cited by 315
DOCKERY, F., BULPITT, C. J., AGARWAL, S., DONALDSON, M., & RAJKUMAR, C. (2003) · Clinical Science · doi:10.1042/cs1040195 · Cited by 294 · cited 3×
“GnRH agonists increase fasting plasma insulin levels in men with prostate cancer (7, 8 ). In contrast to the other reports, however, our study excluded subjects with prevalent diabetes and evaluated whole-body insulin sensitivity index after a glucose load, a more reliable method for assessment of insulin sensitivity…”
BackgroundResultInfluentialChanges in fat and lean body mass during androgen-deprivation therapy for prostate cancer
Smith, M. R. (2004) · Urology · doi:10.1016/j.urology.2003.10.063 · Cited by 259
Self-citationSingh, A. B. (2002) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.1.136 · Cited by 226
Bone Loss in Men with Prostate Cancer Treated with Gonadotropin-Releasing Hormone Agonists1
Stoch, S. A., Parker, R. A., Chen, L., Bubley, G., Ko, Y.-J., Vincelette, A., & Greenspan, S. L. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.6.7558 · Cited by 186
Bone Loss in Men with Prostate Cancer Treated with Gonadotropin-Releasing Hormone Agonists
Stoch, S. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.6.2787 · Cited by 150
Sluiter, W. J., Erkelens, D. W., Reitsma, W. D., & Doorenbos, H. (1976) · Diabetes · doi:10.2337/diab.25.4.241 · Cited by 128 · cited 2×
“Glycoslyated hemoglobin (%) 5.46 0.09 5.62 0.09 2.9 0.8 0.001 Fasting plasma glucose (mg/dl) 93 29 5 2 2.0 1.4 0.20 2-h plasma glucose (mg/dl) 128 7 126 9 4.4 7.5 0.84 Fasting plasma insulin (mU/liter) 13.5 0.9 17.0 2.0 25.9 9.3 0.04 Whole-body ISI (18) 3.4 0.4 2.8 0.3 -12.9 7.6 0.02 HOMA IR (19) 7.1 0.9 5.9 0.6 -12.8…”
MethodInfluentialEri, L. M., Urdal, P., & Bechensteen, A. G. (1995) · Journal of Urology · doi:10.1016/s0022-5347(01)67239-2 · Cited by 100 · cited 1×
“Consistent with earlier reports (5, 8, 22 ), we observed that”
ResultTayek, J., Heber, D., Byerley, L., Steiner, B., Rajfer, J., & Swerdloff, R. S. (1990) · Metabolism: Clinical and Experimental · doi:10.1016/0026-0495(90)90190-n · Cited by 78
Gene therapy for prostate cancer.
Hrouda, D., Perry, M. J. A., & Dalgleish, A. G. (1999) · PubMed · Cited by 53
Eri, L. M., Urdal, P., & Bechensteen, A. G. (1995) · The Journal of Urology · doi:10.1097/00005392-199507000-00035 · Cited by 12
Cited by
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572
Insulin and insulin-like growth factor signalling in neoplasia
Pollak, M. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2536 · Cited by 2,059
“This has been studied with respect to its adverse effects on non-prostate cancer morbidity and mortality in these me”
BackgroundDiabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer
Keating, N. L., O'Malley, A. J., & Smith, M. R. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.2497 · Cited by 1,455
Self-citationHormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline
Fleseriu, M., Hashim, I. A., Karavitaki, N., Melmed, S., Murad, M. H., Salvatori, R., & Samuels, M. H. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2118 · Cited by 945
Mohler, J., Bahnson, R. R., Boston, B., Busby, J. E., D'Amico, A., Eastham, J. A., Enke, C. A., George, D., Horwitz, E. M., Huben, R. P., et al. (2010) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2010.0012 · Cited by 897
Self-citation
Metadata
- Authors
- Smith, M. R., Lee, H., & Nathan, D. M.
- Affiliations
- Massachusetts General Hospital (US)
- Corresponding author
- Smith, Matthew R.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2006-04
- Volume
- 91
- Issue
- 4
- Pages
- 1305-1308
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2129509910
- Cited by
- 493
- References
- 25
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 14 · 2023: 12 · 2022: 13 · 2021: 9 · 2020: 14 · 2019: 15 · 2018: 20 · 2017: 25 · 2016: 24 · 2015: 26 · 2014: 26 · 2013: 35 · 2012: 46
- FWCI
- 32.81
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Prostate Cancer Foundation
- Massachusetts General Hospital
- National Institutes of Health
- National Cancer Institute (P50 CA 90381, P50CA090381)
- National Center for Research Resources (M01RR001066, M01-RR01066)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Keywords
- insulin sensitivity, prostate cancer, combined androgen blockade, GnRH agonist, leuprolide, bicalutamide, fat mass, insulin resistance, diabetes risk, cardiovascular risk, fasting insulin, HbA1c
- MeSH terms
- Adipose Tissue, Adult, Androgen Antagonists, Anthropometry, Blood Glucose, Body Composition, Glucose Tolerance Test, Glycated Hemoglobin, Humans, Insulin, Insulin Resistance, Gonadotropin-Releasing Hormone, Lipids, Male, Prospective Studies, Prostatic Neoplasms, Testosterone, Biomarkers, Absorptiometry, Photon, Treatment Outcome, Antineoplastic Agents, Hormonal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.